Monoclonal antibodies (mAbs) are used as immunotherapeutics to treat cancer and other diseases, and either aim to induce target cell destruction or immune cell activation. After binding to their cognate antigens, mAbs engage Fc gamma receptor (FcγR), localised on the surface of the Immune cells, and identified by many research groups as regulator of mAbs activity. To help researchers working on immunotherapeutic mAbs development, BPS Bioscience have developed a new CHO K1 cell line stably expressing full length human FcGR2B.
Cell-Based ELISA tests now enable precise measurement of the phosphorylation status or expression profiles of target proteins (biomarkers) in whole cells. In this post, a review of high performing cell-based assays is made.
Cell-based assays have become a classic way to monitor cells’ reactions to a treatment or a specific stimulus. They involve a reporter construction and a detection system. The classic system is Firefly Luciferase, combined or not with Renilla Luciferase. Luciferases allow simple data acquisition on a plate reader.
Nevertheless, Firefly Luciferase requires cell lysis. End-point acquisition is the only method and optimizations of the right moment is recommended. To bring more convenience, robustness and higher sensitivity, Gaussian luciferase can well be your better choice.
As a regulator of the immune system, Immune checkpoints appear to be privileged targets In Drug Discovery and Immunotherapy research. Indeed, promising molecules tested in clinical trials and approved are giving new hope for cancer treatment. Beyond checkpoint receptors, the Enzymatic pathway also regulates the immune system and provides additional targets for Drug Development, and may increase the chances of clinical success in Cancer treatment.
In addition to already developed Immune Checkpoint Reporter cell lines (as introduced in my previous post), BPS Bioscience also provide tools to study the enzymatic pathway, such as the tryptophan catabolism pathway controlled by IDO1: The IDO / TDO pathway.